

- 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recomm Rep* 1992;41:1-19.
- Yarchoan R, Mitsuya H, Myers CE, et al. Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. *N Engl J Med* 1989;321:726-738.
- Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. *J Infect Dis* 2006;194:11-19.
- Department of Health & Human Services. *Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents*. Washington, DC: Department of Health & Human Services; 2013.
- Lundgren JD, Babiker A, El-Sadr W, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. *J Infect Dis* 2008;197:1145-1155.
- Baker JV, Peng C, Rapkin J, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. *AIDS* 2008;22:841-848.
- Bonnet F, Burly C, Lewden C, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 Survey. *Clin Infect Dis* 2009;48:633-639.
- Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet* 2009;373:1352-1363.
- Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. *N Engl J Med* 2009;360:1815-1826.
- Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med* 2011;365:493-505.
- Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. *J Natl Cancer Inst* 2011;103:753-762.
- Biggar RJ. Survival after cancer diagnosis in persons with AIDS. *J Acquir Immune Defic Syndr* 2005;39:293.
- Centers for Disease Control and Prevention. *HIV surveillance report, 2011*. Atlanta, GA: Centers for Disease Control and Prevention; 2011.
- Yarchoan R, Tosato G, Little RF. Therapy insight: AIDS-related malignancies—the influence of antiviral therapy on pathogenesis and management. *Nat Clin Pract Oncol* 2005;2:406-415.
- Silverberg MJ, Leyden W, Warton EM, et al. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. *J Natl Cancer Inst* 2013;105:350-360.
- Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. *J Clin Oncol* 2003;21:3447-3453.
- Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. *Cancer* 2005;104:1505-1511.
- Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. *Int J Cancer* 2008;123:187-194.
- Silverberg MJ, Abrams DI. AIDS-defining and non-AIDS-defining malignancies: cancer occurrence in the antiretroviral therapy era. *Curr Opin Oncol* 2007;19:446-451.
- Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med* 2010;363:2587-2599.
- Zou S, Glynn S, Kuritzkes D, et al. Hematopoietic cell transplantation and HIV cure: where we are and what next? *Blood* 2013;122:3111-3115.
- Kaposi M. Idiopathisches multiples Pigmentsarkom der Haut. *Arch Derm Syph* 1872;4:265-273.
- Hymes KB, Cheung T, Greene JB, et al. Kaposi's sarcoma in homosexual men—a report of eight cases. *Lancet* 1981;2:598-600.
- Beral V, Peterman TA, Berkelman RL, et al. Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection? *Lancet* 1990;335:123-128.
- Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 1994;266:1865-1869.
- Gao SJ, Kingsley L, Li M, et al. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. *Nat Med* 1996;2:925-928.
- Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. *N Engl J Med* 1998;338:948-954.
- Safai B, Johnson KG, Myskowski PL, et al. The natural history of Kaposi's sarcoma in the acquired immunodeficiency syndrome. *Ann Intern Med* 1985;103:744-750.
- Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. *AIDS* 2006;20:1645-1654.
- Krown SE. Cancer in resource-limited settings. *J Acquir Immune Defic Syndr* 2011;56:297-299.
- Mosam A, Carrara H, Shaik F, et al. Increasing incidence of Kaposi's sarcoma in black South Africans in KwaZulu-Natal, South Africa (1983-2006). *Int J STD AIDS* 2009;20:553-556.
- Parkin DM, Wabinga H, Namboozee S, et al. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. *AIDS* 1999;13:2563-2570.
- Mbulaitwe SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. *Int J Cancer* 2006;118:985-990.
- Martin J, Wenger M, Busakhala N, et al. Prospective evaluation of the impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma in East Africa: findings from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. *13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)*. 2011 November 7-8. Bethesda, MD: Infect Agent Cancer; 2012;7:19.
- Centers for Disease Control and Prevention. Current trends revision of the case definition of acquired immunodeficiency syndrome for national reporting—United States. *MMWR Weekly* 1985;34:373-375.
- International Agency for Research on Cancer. *WHO classification of tumours of haematopoietic and lymphoid tissues*. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
- Levine AM. Lymphoma complicating immunodeficiency disorders. *Ann Oncol* 1994;5:29-35.
- Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood* 2004;103:275-282.
- Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. *Blood* 2006;107:265-276.
- Polesel J, Clifford GM, Rickenbach M, et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. *AIDS* 2008;22:301-306.
- Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. *J Clin Oncol* 1993;11:1099-1107.
- Breen EC, Boscardin WJ, Detels R, et al. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL10, or the IL10 promoter -592 C/C genotype. *Clin Immunol* 2003;109:119-129.
- Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. *J Clin Oncol* 2010;28:773-779.
- Marks MA, Rabkin CS, Engels EA, et al. Markers of microbial translocation and risk of AIDS-related lymphoma. *AIDS* 2013;27:469-474.
- Engels EA, Pfeiffer RM, Landgren O, et al. Immunologic and virologic predictors of AIDS-related non-hodgkin lymphoma in the highly active antiretroviral therapy era. *J Acquir Immune Defic Syndr* 2010;54:78-84.
- Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. *Antivir Ther* 2009;14:1065-1074.
- Zoufaly A, Stellbrink HJ, Heiden MA, et al. Cumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma. *J Infect Dis* 2009;200:79-87.
- Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. *Nat Med* 2006;12:1365-1371.
- Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. *Blood* 2001;98:2339-2344.
- Abayomi EA, Somers A, Grewal R, et al. Impact of the HIV epidemic and anti-retroviral treatment policy on lymphoma incidence and subtypes seen in the Western Cape of South Africa, 2002-2009: preliminary findings of the Tygerberg Lymphoma Study Group. *Transfus Apher Sci* 2011;44:161-166.
- Wiggill TM, Mantina H, Willem P, et al. Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective. *J Acquir Immune Defic Syndr* 2011;56:460-466.
- Lim ST, Karim R, Nathwani BN, et al. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. *J Clin Oncol* 2005;23:4430-4438.
- Gopal S, Patel MR, Yamik EL, et al. Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. *J Natl Cancer Inst* 2013;105:1221-1229.
- Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. *Blood* 2003;101:4653-4659.
- Dunleavy K, Little RF, Pittaluga S, et al. The role of tumor histogenesis, FDG-PET, and short course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. *Blood* 2010;115:3017-3024.
- Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. *N Engl J Med* 2013;369:1915-1925.
- Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. *N Engl J Med* 2002;346:1937-1947.

58. Achenbach CJ, Cole SR, Kitahata MM, et al. Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy. *AIDS* 2011;25:691–700.
59. Uldrick TS, Pipkin S, Scheer S, et al. Factors associated with survival among patients with AIDS-related primary central nervous system lymphoma. *AIDS* 2014;28(3):397–405.
60. Mosthaf FA, Hanhoff NJ, Goetzenich A, et al. High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany: analysis of data collected over a period of 3 years. *Dtsch Med Wochenschr* 2006;131:1849–1852.
61. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. *Int J Epidemiol* 2005;34:121–130.
62. Simard EP, Pfeiffer RM, Engels EA. Mortality due to cancer among people with AIDS: a novel approach using registry-linkage data and population attributable risk methods. *AIDS* 2012;26:1311–1318.
63. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. *Cancer* 2004;101:317–324.
64. Feng H, Shuda M, Chang Y, et al. Clonal integration of a polyomavirus in human Merkel cell carcinoma. *Science* 2008;319:1096–1100.
65. Engels EA, Frisch M, Goedert JJ, et al. Merkel cell carcinoma and HIV infection. *Lancet* 2002;359:497–498.
66. Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. *J Clin Oncol* 2006;24:1385–1388.
67. Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. *AIDS* 2012;26:1017–1025.
68. Shebl FM, Engels EA, Goedert JJ, et al. Pulmonary infections and risk of lung cancer among persons with AIDS. *J Acquir Immune Defic Syndr* 2010;55:375–379.
69. Skobe M, Brown LF, Tognazzi K, et al. Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. *J Invest Dermatol* 1999;113:1047–1053.
70. Wang HW, Trotter MW, Lagos D, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. *Nat Genet* 2004;36:687–693.
71. Hong YK, Foreman K, Shin JW, et al. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. *Nature Genet* 2004;36:683–685.
72. Rabkin CS, Janz S, Lash A, et al. Monoclonal origin of multicentric Kaposi's sarcoma lesions. *N Engl J Med* 1997;336:988–993.
73. Gill PS, Tsai YC, Rao AP, et al. Evidence for multiclonality in multicentric Kaposi's sarcoma. *Proc Natl Acad Sci U S A* 1998;95:8257–8261.
74. Boshoff C, Endo Y, Collins PD, et al. Angiogenic and HIV-inhibitory functions of KSHV-encoded chemokines. *Science* 1997;278:290–294.
75. Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. *Nature* 1998;391:86–89.
76. Uldrick TS, Whitby D. Update on KSHV epidemiology, Kaposi sarcoma pathogenesis, and treatment of Kaposi sarcoma. *Cancer Lett* 2011;305:150–162.
77. Gallaher AM, Das S, Xiao Z, et al. Proteomic screening of human targets of viral microRNAs reveals functions associated with immune evasion and angiogenesis. *PLoS Pathog* 2013;9:e1003584.
78. Sodhi A, Montaner S, Patel V, et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. *Cancer Res* 2000;60:4873–4880.
79. Montaner S, Sodhi A, Ramsdell AK, et al. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. *Cancer Res* 2006;66:168–174.
80. Crisotto MG, Garin A, Martin AP, et al. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. *J Clin Invest* 2006;116:1264–1273.
81. Moore PS, Boshoff C, Weiss RA, et al. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. *Science* 1996;274:1739–1744.
82. Gasperini P, Espigol-Frigole G, McCormick PJ, et al. Kaposi sarcoma herpesvirus promotes endothelial-to-mesenchymal transition through Notch-dependent signaling. *Cancer Res* 2012;72:1157–1169.
83. Moses AV, Jarvis MA, Raggio C, et al. Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells. *J Virol* 2002;76:8383–8399.
84. Lambert M, Gannage M, Karras A, et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. *Blood* 2006;108:3871–3880.
85. Guihot A, Dupin N, Marcelin AG, et al. Low T cell responses against human herpesvirus-8 in patients with AIDS-related and classic Kaposi sarcoma. *J Infect Dis* 2006;194:1078–1088.
86. Mbulaiteye SM, Biggar RJ, Goedert JJ, et al. Immune deficiency and risk for malignancy among persons with AIDS. *J Acquir Immune Defic Syndr* 2003;32:527–533.
87. Brown EE, Whitby D, Vitale F, et al. Virologic, hematologic, and immunologic risk factors for classic Kaposi sarcoma. *Cancer* 2006;107:2282–2290.
88. Unemori P, Leslie KS, Hunt PW, et al. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. *AIDS* 2013;27:1735–1742.
89. Bihl F, Mosam A, Henry LN, et al. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma. *AIDS* 2007;21:1245–1252.
90. Barozzi P, Bonini C, Potenza L, et al. Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. *Transplantation* 2008;86:738–744.
91. Barozzi P, Potenza L, Riva G, et al. Changes in T-cell responses against human herpesvirus-8 correlate with the disease course of iatrogenic Kaposi's sarcoma in a patient with undifferentiated arthritis. *Semin Arthritis Rheum* 2009;39:170–175.
92. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma-associated herpesvirus (KSHV) infectivity. *Blood* 2004;104:810–814.
93. Krown SE, Testa MA, Huang J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. *J Clin Oncol* 1997;15:3085–3092.
94. Nasti G, Talamini R, Antinori A, et al. AIDS-related Kaposi's sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. *J Clin Oncol* 2003;21:2876–2882.
95. Mosam A, Shaik F, Uldrick TS, et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy-naive patients with HIV-associated Kaposi sarcoma in South Africa. *J Acquir Immune Defic Syndr* 2012;60:150–157.
96. Palmieri C, Dhillon T, Thirlwell C, et al. Pulmonary Kaposi sarcoma in the era of highly active antiretroviral therapy. *HIV Med* 2006;7:291–293.
97. Nasti G, Serraino D, Ridolfo A, et al. AIDS-associated Kaposi's sarcoma is more aggressive in women: a study of 54 patients. *J Acquir Immune Defic Syndr Hum Retrovirol* 1999;20:337–341.
98. Meditz AL, Borok M, MaWhinney S, et al. Gender differences in AIDS-associated Kaposi sarcoma in Harare, Zimbabwe. *J Acquir Immune Defic Syndr* 2007;44:306–308.
99. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. *J Clin Oncol* 1989;7:1201–1207.
100. Gill PS, Loureiro C, Bernstein-Singer M, et al. Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). *Ann Intern Med* 1989;110:937–940.
101. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. *Ann Intern Med* 2007;147:836–839.
102. Krown SE. Highly active antiretroviral therapy in AIDS-associated Kaposi's sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi's sarcoma. *J Clin Oncol* 2004;22:399–402.
103. Bower M, Weir J, Francis N, et al. The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. *AIDS* 2009;23:1701–1706.
104. Sgadari C, Barillari G, Toschi E, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. *Nat Med* 2002;8:225–232.
105. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. *AIDS* 2003;17:F17–F22.
106. Martinez V, Caumes E, Gambotti L, et al. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. *Br J Cancer* 2006;94:1000–1006.
107. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. *J Clin Oncol* 2005;23:5224–5228.
108. Letang E, Lewis JJ, Bower M, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. *AIDS* 2013;27:1603–1613.
109. Webster-Cyriaque J. Development of Kaposi's sarcoma in a surgical wound. *N Engl J Med* 2002;346:1207–1210.
110. Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. *Am J Clin Dermatol* 2001;2:77–87.
111. Duvic M, Friedman-Kien AE, Looney DJ, et al. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. *Arch Dermatol* 2000;136:1461–1469.
112. Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. *J Acquir Immune Defic Syndr* 1999;22:235–246.
113. Tappero JW, Grekin RC, Zanelli GA, et al. Pulsed-dye laser therapy for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. *J Am Acad Dermatol* 1992;27:526–530.

114. Martin-Carbonero L, Palacios R, Valencia E, et al. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin. *Clin Infect Dis* 2008;47:410–417.
115. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. *Cancer* 2010;116:3969–3977.
116. Welles L, Saville MW, Lietzau J, et al. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. *J Clin Oncol* 1998;16:1112–1121.
117. Gill PS, Tulpule A, Espina BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. *J Clin Oncol* 1999;17:1876–1883.
118. Evans SR, Krown SE, Testa MA, et al. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. *J Clin Oncol* 2002;20:3236–3241.
119. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. *J Clin Oncol* 1996;14:2353–2364.
120. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. *J Clin Oncol* 1998;16:2445–2451.
121. Krown SE, Real FX, Cunningham-Rundles S, et al. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. *N Engl J Med* 1983;308:1071–1076.
122. Krown SE. AIDS-associated Kaposi's sarcoma: Is there still a role for interferon alpha? *Cytokine Growth Factor Rev* 2007;18:395–402.
123. Krown SE, Lee JY, Lin L, et al. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial. *J Acquir Immune Defic Syndr* 2006;41:149–153.
124. Kingham TP, Alatise OI, Vanderpuye V, et al. Treatment of cancer in sub-Saharan Africa. *Lancet Oncol* 2013;14:e158–e167.
125. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. *N Engl J Med* 1999;340:1063–1070.
126. Krown SE, Dittmer DP, Cesarman E. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. *J Infect Dis* 2011;203:1082–1086.
127. Little RF, Merced-Galindez F, Staskus K, et al. A pilot study of cidofovir in patients with Kaposi's sarcoma. *J Infect Dis* 2003;187:149–153.
128. Little RF, Pluda JM, Wyvill KM, et al. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. *Blood* 2006;107:4650–4657.
129. Little RF, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma. *Blood* 2007;110:4165–4171.
130. Fife K, Howard MR, Gracie F, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. *Int J STD AIDS* 1998;9:751–755.
131. Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. *J Clin Oncol* 2000;18:2593–2602.
132. Uldrick TS, Polizzotto MN, Yarchoan R. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. *Curr Opin Oncol* 2012;24:495–505.
133. Koon HB, Honda K, Lee JY, et al. Phase II AIDS Malignancy Consortium (AMC) trial of imatinib in AIDS-associated Kaposi's sarcoma (KS). *12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies*. Bethesda, MD: Infectious Agents and Cancer; 2010:5:A61.
134. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. *N Engl J Med* 2005;352:1317–1323.
135. Krown SE, Roy D, Lee JY, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. *J Acquir Immune Defic Syndr* 2012;59:447–454.
136. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castlemans disease. *Blood* 1995;86:1276–1280.
137. Soulier J, Grollet L, Oksenhendler E, et al. Molecular analysis of clonality in Castlemans disease. *Blood* 1995;86:1131–1138.
138. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castlemans disease. *Ann Oncol* 2009;20:775–779.
139. Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease: a pilot study of virus-activated cytotoxic therapy. *Blood* 2011;117:6977–6986.
140. Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castlemans disease. *Blood* 2013;122:4189–4198.
141. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castlemans disease in HIV infection: a clinical and pathological study of 20 patients. *AIDS* 1996;10:61–67.
142. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castlemans disease: ANRS 117 Castlemans Trial. *J Clin Oncol* 2007;25:3350–3356.
143. Hoffmann C, Schmid H, Muller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castlemans disease. *Blood* 2011;118:3499–3503.
144. Gerard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castlemans disease. *Blood* 2012;119:2228–2233.
145. Uldrick TS, Polizzotto M, O'Mahony D, et al. Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi Sarcoma-associated Herpes Virus (KSHV)-associated Multicentric Castlemans Disease (MCD). *12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies: Basic, Epidemiologic, and Clinical Research*. Bethesda, MD; 2010.
146. Stebbing J, Ngan S, Ibrahim H, et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castlemans disease. *Clin Exp Immunol* 2008;154:399–405.
147. Polizzotto MN, Jones P, Cameron PU, et al. The influence of splenectomy on the infectious complications and outcomes of people with HIV: marked, sustained elevation in risk of severe infection with bacteria including *Streptococcus pneumoniae*. *J Acquir Immune Defic Syndr* 2010;55:e24–e26.
148. Uldrick TS, Wang V, O'Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castlemans disease. *Clin Infect Dis* 2010;51:350–358.
149. Polizzotto MN, Uldrick TS, Hu D, et al. Clinical manifestations of Kaposi Sarcoma Herpesvirus lytic activation: Multicentric Castlemans Disease (KSHV/MCD) and the KSHV inflammatory cytokine syndrome. *Front Microbiol* 2012;3:73.
150. Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. *N Engl J Med* 1997;336:1641–1648.
151. Miralles P, Berenguer J, Ribera JM, et al. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors. *J Acquir Immune Defic Syndr* 2007;44:167–173.
152. Wong HL, Breen EC, Pfeiffer RM, et al. Cytokine signaling pathway polymorphisms and AIDS-related non-Hodgkin lymphoma risk in the multicenter AIDS cohort study. *AIDS* 2010;24:1025–1033.
153. Breen EC, Fatahi S, Epeldegui M, et al. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. *Tumour Biol* 2006;27:187–194.
154. Rabkin CS, Yang Q, Goedert JJ, et al. Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-1-infected individuals. *Blood* 1999;93:1838–1842.
155. Dean M, Jacobson LP, McFarlane G, et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. *Cancer Res* 1999;59:3561–3564.
156. He B, Raab-Traub N, Casali P, et al. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. *J Immunol* 2003;171:5215–5224.
157. Epeldegui M, Thapa DR, De la Cruz J, et al. CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. *PLoS One* 2010;5:e11448.
158. Imbeault M, Ouellet M, Giguere K, et al. Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment. *J Virol* 2011;85:2189–2200.
159. Gaidano G, Pasqualucci L, Capello D, et al. Aberrant somatic hypermutation in multiple subtypes of AIDS-associated non-Hodgkin lymphoma. *Blood* 2003;102:1833–1841.
160. Epeldegui M, Breen EC, Hung YP, et al. Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS-NHL diagnosis. *AIDS* 2007;21:2265–2270.
161. Pasqualucci L, Bhagat G, Jankovic M, et al. AID is required for germinal center-derived lymphomagenesis. *Nat Genet* 2008;40:108–112.
162. Liapis K, Clear A, Owen A, et al. The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. *Blood* 2013;122:424–433.
163. Valera A, Balague O, Colomo L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. *Am J Surg Pathol* 2010;34:1686–1694.
164. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. *Cancer* 2011;117:1089–1096.
165. Lanoy E, Rosenberg PS, Fily F, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. *Blood* 2011;118:44–49.
166. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. *J Clin Oncol* 2001;19:2171–2178.
167. Boue F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. *J Clin Oncol* 2006;24:4123–4128.

168. Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. *Br J Haematol* 2008;140:411–419.
169. Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. *AIDS* 2001;15:1483–1491.
170. Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. *Blood* 2013;122:3251–3262.
171. Carbone A, Gloghini A, Larocca LM, et al. Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. *Blood* 2001;97:744–751.
172. Dunleavy K, Wilson WH. Role of molecular subtype in predicting outcome of AIDS-related diffuse large B-cell lymphoma. *J Clin Oncol* 2010;28:e260.
173. de Witt P, Maertens DJ, Uldrick TS, et al. Treatment outcomes in AIDS-related diffuse large B-cell lymphoma in the setting roll out of combination antiretroviral therapy in South Africa. *J Acquir Immune Defic Syndr* 2013;64:66–73.
174. Chadburn A, Chiu A, Lee JY, et al. Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. *J Clin Oncol* 2009;27:5039–5048.
175. Levine AM. HIV-associated lymphoma. *Blood* 2010;115:2986–2987.
176. Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. *Blood* 2010;115:3008–3016.
177. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002;346:235–242.
178. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase III trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin's lymphoma: AIDS-malignancies consortium trial 010. *Blood* 2005;106:1538–1543.
179. Spina M, Jaeger U, Sparano JA, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials. *Blood* 2005;105:1891–1897.
180. Ling SM, Roach M 3rd, Larson DA, et al. Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. *Cancer* 1994;73:2570–2582.
181. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. *Cancer* 2004;100:2627–2636.
182. Cingolani A, De Luca A, Larocca LM, et al. Minimally invasive diagnosis of acquired immunodeficiency syndrome-related primary central nervous system lymphoma. *J Natl Cancer Inst* 1998;90:364–369.
183. Larocca LM, Capello D, Rinelli A, et al. The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. *Blood* 1998;92:1011–1019.
184. Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuro-radiologic characteristics combined with polymerase chain reaction assays in CSF. *Neurology* 1997;48:687–694.
185. Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. *J Nucl Med* 1993;34:567–575.
186. O'Doherty MJ, Barrington SF, Campbell M, et al. PET scanning and the human immunodeficiency virus-positive patient. *J Nucl Med* 1997;38:1575–1583.
187. Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. *J Clin Oncol* 2000;18:3325–3330.
188. Corcoran C, Rebe K, van der Plas H, et al. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. *J Clin Virol* 2008;42:433–436.
189. Diamond C, Taylor TH, Im T, et al. Highly active antiretroviral therapy is associated with improved survival among patients with AIDS-related primary central nervous system non-Hodgkin's lymphoma. *Curr HIV Res* 2006;4:375–378.
190. Nagai H, Odawara T, Ajisawa A, et al. Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. *Eur J Haematol* 2010;84:499–505.
191. Fisher B, Seiferheld W, Schultz C, et al. Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310: an intergroup phase II combined modality treatment of primary central nervous system lymphoma. *J Neurooncol* 2005;74:201–205.
192. Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous System Lymphoma Collaborative Group Report. *Cancer* 2010;116:863–870.
193. Rubenstein J, Ferreri AJ, Pitaluga S. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. *Leuk Lymphoma* 2008;49:43–51.
194. Gerstner ER, Hochberg FH, Plotkin SR, et al. High-dose methotrexate, rituximab, and temozolomide (MRT) for patients with primary CNS lymphoma (PCNSL). *51st American Society of Hematology Annual Meeting*. New Orleans, LA; 2009.
195. Nicol I, Boye T, Carsuzaa F, et al. Post-transplant plasmablastic lymphoma of the skin. *Br J Dermatol* 2003;149:889–891.
196. Verma S, Nuovo GJ, Porcu P, et al. Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation. *J Cutan Pathol* 2005;32:35–39.
197. Thakral C, Thomas L, Gajra A, et al. Plasmablastic lymphoma in an immunocompetent patient. *J Clin Oncol* 2009;27:e78–e81.
198. Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. *Am J Hematol* 2008;83:804–809.
199. Schommers P, Wyen C, Hentrich M, et al. Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. *AIDS* 2013;27:842–845.
200. Noy A, Chadburn A, Lensing SY, et al. Plasmablastic lymphoma is curable in the HAART era. A 10 year retrospective by The AIDS Malignancy Consortium (AMC). *55th American Society of Hematology Annual Meeting*. New Orleans, LA; 2013:Abstract 1801.
201. Uldrick TS, Polizzotto MN, Filie A, et al. Clinical, immunologic, and virologic findings in Kaposi sarcoma herpesvirus (KSHV)-associated lymphomas suggest KSHV-associated inflammatory syndromes contribute to symptoms and disease pathogenesis. *54th American Society of Hematology Annual Meeting*. Atlanta, GA; 2012. Abstract 2708.
202. Carbone A, Gloghini A, Vaccher E, et al. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. *J Mol Diagn* 2005;7:17–27.
203. Boulanger E, Gerard L, Gabarre J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS. *J Clin Oncol* 2005;23:4372–4380.
204. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. *Ann Oncol* 2002;13:1264–1274.
205. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma. *Cancer* 2003;98:1196–1205.
206. Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. *AIDS* 2010;24:851–856.
207. Noy A, Kaplan L, Lee JY. A modified dose intensive R-CODOX-M/IVAC for HIV-associated Burkitt and atypical Burkitt lymphoma (BL) demonstrates high cure rates and low toxicity: prospective multicenter phase II trial of The AIDS Malignancy Consortium (AMC 048). *55th American Society of Hematology Annual Meeting*. New Orleans, LA; 2013. Abstract 639.
208. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. *Cancer* 2002;94:1492–1499.
209. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. *Blood* 2006;108:3786–3791.
210. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. *J Clin Oncol* 1995;13:1758–1767.
211. Hoffmann C, Chow KU, Wolf E, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. *Br J Haematol* 2004;125:455–462.
212. Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. *J Clin Oncol* 2012;30:4117–4123.
213. Bohlius J, Schmidlin K, Boue F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4(+) T-cell lymphocytes. *Blood* 2011;117:6100–6108.
214. Fardet L, Lambotte O, Meynard JL, et al. Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. *AIDS* 2010;24:1299–1306.
215. Montoto S, Shaw K, Okosun J, et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. *J Clin Oncol* 2012;30:4111–4116.
216. Xicoy B, Ribera JM, Miralles P, et al. Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. *Leuk Lymphoma* 2009;50:1718–1720.
217. Ezzat HM, Cheung MC, Hicks LK, et al. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. *Leuk Lymphoma* 2012;53:2390–2396.
218. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. *Blood* 2005;105:874–878.

219. Spitzer TR, Ambinder RF, Lee JY, et al. Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020. *Biol Blood Marrow Transplant* 2008;14:59–66.
220. Re A, Michieli M, Casari S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. *Blood* 2009;114:1306–1313.
221. Balsalobre P, Diez-Martin JL, Re A, et al. Autologous stem-cell transplantation in patients with HIV-related lymphoma. *J Clin Oncol* 2009;27:2192–2198.
222. Bayraktar UD, Ramos JC, Petrich A, et al. Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999–2008 and treated with curative intent in the AIDS Malignancy Consortium. *Leuk Lymphoma* 2012;53:2383–2389.
223. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. *N Engl J Med* 2009;360:692–698.
224. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. *J Natl Cancer Inst* 2000;92:1500–1510.
225. Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus-associated cancers among persons with AIDS. *J Natl Cancer Inst* 2009;101:1120–1130.
226. Wright TC Jr, Ellerbrock TV, Chiasson MA, et al. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. *Obstet Gynecol* 1994;84:591–597.
227. Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. *Obstet Gynecol* 1994;83:205–211.
228. Minkoff H, Zhong Y, Burk RD, et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. *J Infect Dis* 2010;201:681–690.
229. Blitz S, Baxter J, Raboud J, et al. Evaluation of HIV and highly active antiretroviral therapy on the natural history of human papillomavirus infection and cervical cytopathologic findings in HIV-positive and high-risk HIV-negative women. *J Infect Dis* 2013;208:454–462.
230. Adler DH, Kakinami L, Modisenyane T, et al. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. *AIDS* 2012;26:1645–1652.
231. Bertisch B, Franceschi S, Lise M, et al. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. *Am J Epidemiol* 2013;178:877–884.
232. Guiguet M, Boue F, Cadranel J, et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. *Lancet Oncol* 2009;10:1152–1159.
233. Heard I. Prevention of cervical cancer in women with HIV. *Curr Opin HIV AIDS* 2009;4:68–73.
234. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. *MMWR Recomm Rep* 2006;55:1–94.
235. Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. *Am J Med* 2001;111:140–149.
236. Maiman M, Fruchter RC, Serur E, et al. Recurrent cervical intraepithelial neoplasia in human immunodeficiency virus-seropositive women. *Obstet Gynecol* 1993;82:170–174.
237. Massad LS, Fazzari MJ, Anastos K, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. *J Low Genit Tract Dis* 2007;11:90–97.
238. Denny L, Kuhn L, Hu CC, et al. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. *J Natl Cancer Inst* 2010;102:1557–1567.
239. Kuhn L, Wang C, Tsai WY, et al. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. *AIDS* 2010;24:2553–2561.
240. Sahasrabudhe VV, Parham GP, Mwanahamuntu MH, et al. Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential. *Cancer Prev Res* 2012;5:11–17.
241. Mwanahamuntu MH, Sahasrabudhe VV, Kapambwe S, et al. Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the Cervical Cancer Prevention Program in Zambia. *PLoS Med* 2011;8:e1001032.
242. Brust D, Polis M, Davey R, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. *AIDS* 2006;20:495–503.
243. Palefsky JM. Anal cancer prevention in HIV-positive men and women. *Curr Opin Oncol* 2009;21:433–438.
244. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. *JAMA* 1999;281:1822–1829.
245. Kreuter A, Potthoff A, Brockmeyer NH, et al. Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. *J Invest Dermatol* 2008;128:2078–2083.
246. Sanclemente G, Herrera S, Tyring SK, et al. Human papillomavirus (HPV) viral load and HPV type in the clinical outcome of HIV-positive patients treated with imiquimod for anogenital warts and anal intraepithelial neoplasia. *J Eur Acad Dermatol Venereol* 2007;21:1054–1060.
247. Stier EA, Goldstone SE, Einstein MH, et al. Safety and efficacy of topical cidofovir to treat of high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women. *AIDS* 2013;27:545–551.
248. Goldstone SE, Hundert JS, Huyett JW. Infrared coagulator ablation of high-grade anal squamous intraepithelial lesions in HIV-negative males who have sex with males. *Dis Colon Rectum* 2007;50:565–575.
249. Stier EA, Goldstone SE, Berry JM, et al. Infrared coagulator treatment of high-grade anal dysplasia in HIV-infected individuals: an AIDS malignancy consortium pilot study. *J Acquir Immune Defic Syndr* 2008;47:56–61.
250. Hoffman R, Welton ML, Klencke B, et al. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. *Int J Radiat Oncol Biol Phys* 1999;44:127–131.
251. Abramowitz L, Mathieu N, Roudot-Thoraval F, et al. Epidermoid anal cancer prognosis comparison among HIV+ and HIV- patients. *Aliment Pharmacol Ther* 2009;30:414–421.
252. Kang EM, de Witte M, Malech H, et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. *Blood* 2002;99:698–701.
253. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: treatment considerations and research outlook. *Curr Opin Oncol* 2009;21:445–454.
254. Deeken JF, Mitsuyasu RT, Little RF, et al. Treating HIV+ patients for non-AIDS-defining cancers (NADCs) in the era of targeted chemotherapy: An AIDS malignancy consortium study of sunitinib in patients on ART. *2010 ASCO Annual Meeting*. Chicago, IL: American Society of Clinical Oncology; 2010.
255. Persad GC, Little RF, Grady C. Including persons with HIV infection in cancer clinical trials. *J Clin Oncol* 2008;26:1027–1032.
256. Sparano JA, Lee S, Chen MG, et al. Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). *J Clin Oncol* 2004;22:1491–1500.